• Citer

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

par Incorvaia, Lorena;Fanale, Daniele;Badalamenti, Giuseppe;Porta, Camillo;Olive, Daniel;De Luca, Ida;Brando, Chiara;Rizzo, Mimma;Messina, Carlo;Rediti, Mattia ;Russo, Antonio;Bazan, Viviana;Iovanna, Juan-Lucio
Référence Oncoimmunology, 9, 1, 1832348
Publication Publié, 2020-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
Auteur:	Incorvaia, Lorena; Fanale, Daniele; Badalamenti, Giuseppe; Porta, Camillo; Olive, Daniel; De Luca, Ida; Brando, Chiara; Rizzo, Mimma; Messina, Carlo; Rediti, Mattia; Russo, Antonio; Bazan, Viviana; Iovanna, Juan-Lucio
Informations sur la publication:	Oncoimmunology, 9, 1, 1832348
Statut de publication:	Publié, 2020-01
Sujet CREF:	Immunologie
	Allergie et immunopathologie
	Physique de l'état solide
	Métallurgie
Mots-clés:	BTN2A1
	BTN3A1
	butyrophilins
	circulating immune checkpoints
	immunotherapy response
	PD-1
	PD-L1
	predictive biomarker
	renal cell carcinoma
	soluble immune-checkpoints
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:2162-4011
	info:doi/10.1080/2162402X.2020.1832348
	info:scp/85094863210